8 June 2018 - - South San Francisco, California-based clinical-stage biotechnology company Vaxart, Inc. has reported topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel for the treatment of condyloma, or anogenital warts, the company said.
This teslexivir trial was a Phase 2 double-blind, randomized, placebo-controlled trial designed to evaluate teslexivir 5% gel dosed topically twice daily in 218 male and female patients with condyloma.
The primary efficacy endpoint of complete clearance of baseline condyloma by week 16 was not met in the trial with the differences between the placebo and drug treatment groups being not statistically significant.
Teslexivir is a topical antiviral agent that is a potent and selective inhibitor of the interaction between two essential viral proteins, E1 and E2, an interaction that is a necessary step for human papilloma virus DNA replication and thus viral production.
Vaxart is focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company's oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer.
Its development programs include oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus.